PBAC's latest decision on Vinorelbine tartrate: Recommended with restriction (2006). Considered for locally advanced or metastatic non-small cell lung cancer.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
patients with locally advanced or metastatic non-small cell lung cancer
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
RCT, Single-arm
Primary endpoint
ORR, PFS, OS
Pivotal trial size
115 patients
Key trials
CA205, CA201, CA206, CA208, CA102
Comparator
intravenous vinorelbine
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated